<DOC>
	<DOC>NCT00238485</DOC>
	<brief_summary>This extension study is designed to investigate the long-term safety and tolerability of licarbazepine 750-2000 mg/d over 52 weeks in patients who completed the 6-week double-blind study CLIC477D2302.</brief_summary>
	<brief_title>An Open-label Extension Study to Evaluate the Safety and Tolerability of Licarbazepine 750-2000 mg/d in the Treatment of Manic Episodes of Bipolar I Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<criteria>written informed consent provided prior to participation in the extension study. successful completion of the study CLIC477D2302 willingness and ability to comply with all study requirements premature discontinuation from the study CLIC477D2302 failure to comply with the study CLIC477D2302 protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Bipolar I Disorder</keyword>
</DOC>